Latest News
-
REDWOOD CITY, Calif. — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding...
-
MELBOURNE, Australia — Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that the first participant in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial has completed the 36-week placebo-controlled (RCT)...
-
NEW YORK, NY — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Across ten...
